Sign In
Linkedin Youtube
EN ES

Publications

Publication Type
Keywords
Publication Year

Effective incorporation of biospecimen collection for translational studies into a phase III trial: the NEOALTTO experience

Congress Communications
Author:
Nuciforo P, Fumagalli D, Jimenez J, Aura C, Maetens M, Prudkin L, Rothe F, Vasquez J, Loi S, Eidtmann H, Piccart M, Baselga J.
Parent Trial:

NEOALTTO

PI3KCA mutations and correlation with PCR in the NEOALTTO trial (BIG 01-06)

Congress Communications
Author:
Baselga J, Majewski I, Nuciforo PG, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Diaz Delgado MC, Piccart-Gebhart M and Bernards R.
Parent Trial:

NEOALTTO

Pattern of rash, diarrhea, and hepatic toxicities secondary to neoadjuvant lapatinib and their association with age and pathological complete response (PCR) in breast cancer (BC) patients: analysis from the NEOALTTO trial

Congress Communications
Author:
Azim HA, Agbor-tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG, Eidtmann H, Piccart M and De Azambuja E.
Parent Trial:

NEOALTTO

The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in Her2-positive breast cancer. Survival follow-up analysis of NEOALTTO study (BIG 1-06 )

Congress Communications
Author:
Piccart-Gebhart M, Holmes A, de Azambuja E, Di Cosimo S, GSK (TDB), Untch M, Jackish C, Lang L, Smith I, Boyle F, Xu B, Barrios C, Gelber R, Eidtmann H, Baselga J
Parent Trial:

NEOALTTO

10 (PTEN) evaluation in the NEOALTTO trial (BIG 01-06)

Congress Communications
Author:
Nuciforo P, Aura C, Prudkin L, Jimenez J, Martinez P, Peiro N, Ellis C, Eidtmann H, Piccart M, Baselga J.
Parent Trial:

NEOALTTO

Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer

Congress Communications
Author:
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos EM, Ojeda B, Mansutti M, Bozhok A, Magazzu D, Steinseifer J, Valagussa P and Baselga J.
Parent Trial:

NOAH

Adjuvant treatment of premenopausal women with endocrineresponsive early breast cancer: design of the TEXT and SOFT trials

Article
Author:
Meredith M. Regan, Olivia Pagani, Gini F. Fleming , Barbara A. Walley, Karen N. Price, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Alan S. Coates, Aron Goldhirsch, Marco Colleoni, Richard D. Gelber, Prudence A. Francis, on behalf of the International Breast Cancer Study Group (IBCSG) and the SOFT and TEXT Investigators.
Parent Trial:

SOFT

Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients

Article
Author:
Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JR, Sancho de Salas M, Delgado-Sánchez JJ, Pinto W, Gozalbo F, Petit A, Sansano I, Téllez M and Rubio IT.
Parent Trial:

SOLO - SOLTI 1113

Nomogram including total tumoral load as a novel factor predicting nonsentinel node metastasis in breast cancer

Congress Communications
Author:
Rubio I, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez J, Sancho de Salas M, Delgado-Sánchez J, Pinto W, Gozalbo F, Peg V.
Parent Trial:

SOLO - SOLTI 1113

NEOERIBULIN: a phase II, non-randomized, open-label, single-arm, multicenter, exploratory pharmacogenomic study of single agent eribulin as neoadjuvant treatment for operable stage I-II HER2 non-overexpressing breast cancer

Congress Communications
Author:
Prat A, Llombart A, de la Peña L, Di Cosimo S, Ortega V, Rubio I, Muñoz E, Harbeck N, Cortés J.
Parent Trial:

NeoEribulin
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  
X

En Grupo Solti utilizamos cookies, propias y de terceros, analíticas, publicitarias y de elaboración de perfiles, basadas en hábitos de navegación del usuario, para mejorar la calidad del servicio, medir la audiencia y ofrecerle publicidad que pueda ser de su interés. Puede obtener más información en nuestra Política de Cookies.

Entendemos que acepta el uso de cookies en caso de que siga navegando.

Puede gestionar las cookies y aceptarlas o rechazarlas en el Panel de Configuración.